A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome

ConditionSchnitzler Syndrome

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age0+

SponsorNovartis Pharmaceuticals

About this trial

The aim of this study is to assess the effectiveness and safety of Ilaris (canakinumab) in clinical use in patients with Schnitzler's syndrome.

Eligibility criteria

Qualifiers

None

Disqualifiers

Patients previously treated with canakinumab in Study IACT21071.

Patients receiving canakinumab for off-label use under the Clinical Trials Act or GCP (e.g., patient-proposed healthcare services, investigator-initiated clinical trial).

Trial design

Treatments tested in this trial

Not listed

Trial groups

10 Participants

are grouped into 1 trial group

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov